[
  {
    "ts": null,
    "headline": "Is Stryker’s Premium Price Still Justified After Recent Flat Share Performance?",
    "summary": "If you are wondering whether Stryker at around $351 a share is still a smart buy, or if the best days are already priced in, you are not alone. This breakdown aims to unpack that question. The stock is roughly flat this year, down about 2.0% year to date and 4.3% over the last 12 months, but still up 51.8% over 3 years and 57.4% over 5 years. This performance points to a long run of optimism that may now be cooling. Recently, investors have been focused on Stryker's ongoing innovation in...",
    "url": "https://finnhub.io/api/news?id=c38df6ed993a40b4de9858ca0e677d5e63a0c90b2890423945c5825d7f62ffe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765998662,
      "headline": "Is Stryker’s Premium Price Still Justified After Recent Flat Share Performance?",
      "id": 137817271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "If you are wondering whether Stryker at around $351 a share is still a smart buy, or if the best days are already priced in, you are not alone. This breakdown aims to unpack that question. The stock is roughly flat this year, down about 2.0% year to date and 4.3% over the last 12 months, but still up 51.8% over 3 years and 57.4% over 5 years. This performance points to a long run of optimism that may now be cooling. Recently, investors have been focused on Stryker's ongoing innovation in...",
      "url": "https://finnhub.io/api/news?id=c38df6ed993a40b4de9858ca0e677d5e63a0c90b2890423945c5825d7f62ffe5"
    }
  }
]